Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 1.87
BIO's Cash-to-Debt is ranked lower than
60% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. BIO: 1.87 )
Ranked among companies with meaningful Cash-to-Debt only.
BIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.56 Max: 1.94
Current: 1.87
0.03
1.94
Equity-to-Asset 0.73
BIO's Equity-to-Asset is ranked higher than
64% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BIO: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
BIO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.52 Max: 0.73
Current: 0.73
0.33
0.73
Debt-to-Equity 0.10
BIO's Debt-to-Equity is ranked higher than
69% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. BIO: 0.10 )
Ranked among companies with meaningful Debt-to-Equity only.
BIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05  Med: 0.44 Max: 1.24
Current: 0.1
0.05
1.24
Debt-to-EBITDA 0.30
BIO's Debt-to-EBITDA is ranked lower than
52% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. BIO: 0.30 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BIO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.3  Med: 1.71 Max: 2.45
Current: 0.3
0.3
2.45
Interest Coverage 8.42
BIO's Interest Coverage is ranked lower than
79% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. BIO: 8.42 )
Ranked among companies with meaningful Interest Coverage only.
BIO' s Interest Coverage Range Over the Past 10 Years
Min: 2.77  Med: 5.5 Max: 8.42
Current: 8.42
2.77
8.42
Piotroski F-Score: 7
Altman Z-Score: 5.55
Beneish M-Score: -2.36
WACC vs ROIC
9.03%
4.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 8.43
BIO's Operating Margin % is ranked higher than
59% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. BIO: 8.43 )
Ranked among companies with meaningful Operating Margin % only.
BIO' s Operating Margin % Range Over the Past 10 Years
Min: 5.58  Med: 10.13 Max: 14.74
Current: 8.43
5.58
14.74
Net Margin % 45.10
BIO's Net Margin % is ranked higher than
67% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. BIO: 45.10 )
Ranked among companies with meaningful Net Margin % only.
BIO' s Net Margin % Range Over the Past 10 Years
Min: 1.26  Med: 5.54 Max: 45.1
Current: 45.1
1.26
45.1
ROE % 29.06
BIO's ROE % is ranked higher than
61% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. BIO: 29.06 )
Ranked among companies with meaningful ROE % only.
BIO' s ROE % Range Over the Past 10 Years
Min: 1.03  Med: 6.74 Max: 29.06
Current: 29.06
1.03
29.06
ROA % 20.43
BIO's ROA % is ranked higher than
64% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. BIO: 20.43 )
Ranked among companies with meaningful ROA % only.
BIO' s ROA % Range Over the Past 10 Years
Min: 0.69  Med: 3.79 Max: 20.43
Current: 20.43
0.69
20.43
ROC (Joel Greenblatt) % 107.85
BIO's ROC (Joel Greenblatt) % is ranked higher than
59% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. BIO: 107.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.34  Med: 20.83 Max: 107.85
Current: 107.85
6.34
107.85
3-Year Revenue Growth Rate -1.20
BIO's 3-Year Revenue Growth Rate is ranked lower than
66% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. BIO: -1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.8  Med: 8 Max: 21
Current: -1.2
-1.8
21
3-Year EBITDA Growth Rate -5.00
BIO's 3-Year EBITDA Growth Rate is ranked lower than
86% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. BIO: -5.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.4  Med: 7.5 Max: 41.9
Current: -5
-14.4
41.9
3-Year EPS without NRI Growth Rate 10.10
BIO's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. BIO: 10.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.8  Med: 10.1 Max: 112
Current: 10.1
-36.8
112
GuruFocus has detected 4 Warning Signs with Bio-Rad Laboratories Inc BIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIO's 30-Y Financials

Financials (Next Earnings Date: 2018-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

BIO Guru Trades in Q3 2017

Jim Simons 90,600 sh (+4.74%)
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Mariko Gordon 15,478 sh (-0.53%)
Ken Fisher 277,441 sh (-0.77%)
Chuck Royce 105,730 sh (-3.56%)
Mario Gabelli 52,162 sh (-4.40%)
NWQ Managers 287,576 sh (-8.16%)
John Rogers 524,244 sh (-8.71%)
» More
Q4 2017

BIO Guru Trades in Q4 2017

Jeremy Grantham 2,500 sh (New)
Paul Tudor Jones 2,580 sh (New)
Ray Dalio 19,255 sh (New)
Jim Simons 305,300 sh (+236.98%)
Mariko Gordon 15,478 sh (unchged)
Ken Fisher 275,177 sh (-0.82%)
Mario Gabelli 46,762 sh (-10.35%)
NWQ Managers 257,083 sh (-10.60%)
Chuck Royce 81,314 sh (-23.09%)
John Rogers 267,520 sh (-48.97%)
» More
Q1 2018

BIO Guru Trades in Q1 2018

George Soros 75,000 sh (New)
Pioneer Investments 102,527 sh (New)
Steven Cohen 108,200 sh (New)
Chuck Royce 93,560 sh (+15.06%)
Jim Simons 343,700 sh (+12.58%)
Jeremy Grantham 2,600 sh (+4.00%)
Paul Tudor Jones Sold Out
Mariko Gordon Sold Out
Ken Fisher 265,072 sh (-3.67%)
Mario Gabelli 44,112 sh (-5.67%)
John Rogers 251,129 sh (-6.13%)
NWQ Managers 216,030 sh (-15.97%)
Ray Dalio 3,609 sh (-81.26%)
» More
Q2 2018

BIO Guru Trades in Q2 2018

Pioneer Investments 104,199 sh (+1.63%)
Jeremy Grantham 2,600 sh (unchged)
George Soros Sold Out
Ken Fisher 262,697 sh (-0.90%)
Chuck Royce 90,490 sh (-3.28%)
Mario Gabelli 42,112 sh (-4.53%)
John Rogers 231,976 sh (-7.63%)
Steven Cohen 99,603 sh (-7.95%)
Jim Simons 303,000 sh (-11.84%)
NWQ Managers 173,760 sh (-19.57%)
Ray Dalio 1,832 sh (-49.24%)
» More
» Details

Insider Trades

Latest Guru Trades with BIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -0.90%$244.1 - $303.88 $ 317.8815%262,697
John Rogers 2018-06-30 Reduce -7.63%0.05%$244.1 - $303.88 $ 317.8815%231,976
NWQ Managers 2018-06-30 Reduce -19.57%0.17%$244.1 - $303.88 $ 317.8815%173,760
Mario Gabelli 2018-06-30 Reduce -4.53%$244.1 - $303.88 $ 317.8815%42,112
George Soros 2018-06-30 Sold Out 0.35%$244.1 - $303.88 $ 317.8815%0
Ken Fisher 2018-03-31 Reduce -3.67%$233.97 - $274.11 $ 317.8825%265,072
John Rogers 2018-03-31 Reduce -6.13%0.04%$233.97 - $274.11 $ 317.8825%251,129
NWQ Managers 2018-03-31 Reduce -15.97%0.14%$233.97 - $274.11 $ 317.8825%216,030
George Soros 2018-03-31 New Buy0.35%$233.97 - $274.11 $ 317.8825%75,000
Mario Gabelli 2018-03-31 Reduce -5.67%$233.97 - $274.11 $ 317.8825%44,112
Mariko Gordon 2018-03-31 Sold Out 0.23%$233.97 - $274.11 $ 317.8825%0
Ken Fisher 2017-12-31 Reduce -0.82%$216.94 - $269.58 $ 317.8831%275,177
John Rogers 2017-12-31 Reduce -48.97%0.66%$216.94 - $269.58 $ 317.8831%267,520
NWQ Managers 2017-12-31 Reduce -10.60%0.1%$216.94 - $269.58 $ 317.8831%257,083
Mario Gabelli 2017-12-31 Reduce -10.35%0.01%$216.94 - $269.58 $ 317.8831%46,762
John Rogers 2017-09-30 Reduce -8.71%0.13%$212.27 - $242.28 $ 317.8841%524,244
NWQ Managers 2017-09-30 Reduce -8.16%0.08%$212.27 - $242.28 $ 317.8841%287,576
Ken Fisher 2017-09-30 Reduce -0.77%$212.27 - $242.28 $ 317.8841%277,441
Mario Gabelli 2017-09-30 Reduce -4.40%$212.27 - $242.28 $ 317.8841%52,162
Mariko Gordon 2017-09-30 Reduce -0.53%$212.27 - $242.28 $ 317.8841%15,478
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NYSE:QGEN, NYSE:PKI, NAS:DXCM, NAS:ICLR, NAS:EXAS, XPAR:ERF, XTER:AFX, XPAR:BIM, SZSE:300676, XTER:SRT3, NAS:PRAH, MIL:DIA, NYSE:CRL, NAS:BRKR, SHSE:603658, NAS:SYNH, NAS:NEOG, NAS:FMI, BSP:DASA3, BSP:FLRY3 » details
Traded in other countries:BUWA.Germany,
Headquarter Location:USA
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories Inc manufactures and supplies systems used to separate and analyze chemical and biological materials to life sciences and healthcare companies. The firm has two business segments: Life Science and Clinical Diagnostics. The life sciences segment manufactures reagents and laboratory instruments used by researchers, food producers, and pharmaceutical manufacturers. The Clinical Diagnostics segment generates over half of the firm's revenue and sells in vitro diagnostic tests to clinical laboratories. A majority of the firm's revenue is generated outside of the United States.

Top Ranked Articles about Bio-Rad Laboratories Inc

Report: Developing Opportunities within Acxiom, BofI Holding, On Assignment, Marriot Vacations Worldwide, Bio-Rad Laboratories, and Dime Community Bancshares — Future Expectations, Projections Moving into 2018
Ariel Investments on the Future of Health Care Recommends 10 health care names
Ariel Investments, run by John Rogers (Trades, Portfolio), just published an interesting monthly commentary I'll shortly discuss. Very quickly -- who is John Rogers (Trades, Portfolio)? GuruFocus profiles Rogers as follows: Read more...
Pioneer Makes Early Gains on Top Buys of 1st Quarter Sothebys, Alarm.com, Callaway Golf and Bio-Rad are among the new buys for the quarter
Pioneer Investments (Trades, Portfolio) initiated four major positions in its $61.8 billion portfolio of holdings in the early months of the year, according to regulatory filings. Read more...
Research Report Identifies Bio-Rad Laboratories, Bright Horizons Family Solutions, Corbus Pharmaceuticals, PennyMac Financial Services, TeleTech, and Matrix Service with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Detailed Research: Economic Perspectives on CTS, Lindblad Expeditions, AmeriGas Partners, BBX Capital, Bio-Rad Laboratories, and Inter Parfums — What Drives Growth in Today's Competitive Landscape
Analysis: Positioning to Benefit within Oritani Financial, Bio-Rad Laboratories, Compass Diversified, Q2, Medpace, and Engility — Research Highlights Growth, Revenue, and Consolidated Results
Senior Leadership of ARM, Verizon, Blizzard Entertainment, Peregrine Semiconductor, Extel Technologies and Bio-Rad Laboratories join EvoNexus Board of Directors

Ratios

vs
industry
vs
history
PE Ratio 9.33
BIO's PE Ratio is ranked lower than
87% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. BIO: 9.33 )
Ranked among companies with meaningful PE Ratio only.
BIO' s PE Ratio Range Over the Past 10 Years
Min: 8.45  Med: 25.31 Max: 562.76
Current: 9.33
8.45
562.76
Forward PE Ratio 54.64
BIO's Forward PE Ratio is ranked lower than
88% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO: 54.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 9.33
BIO's PE Ratio without NRI is ranked lower than
87% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. BIO: 9.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.45  Med: 25.31 Max: 562.76
Current: 9.33
8.45
562.76
Price-to-Owner-Earnings 8.11
BIO's Price-to-Owner-Earnings is ranked lower than
99.99% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. BIO: 8.11 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.36  Med: 19.96 Max: 232.3
Current: 8.11
7.36
232.3
PB Ratio 2.03
BIO's PB Ratio is ranked higher than
68% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. BIO: 2.03 )
Ranked among companies with meaningful PB Ratio only.
BIO' s PB Ratio Range Over the Past 10 Years
Min: 1.45  Med: 1.79 Max: 3.02
Current: 2.03
1.45
3.02
PS Ratio 4.23
BIO's PS Ratio is ranked higher than
50% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. BIO: 4.23 )
Ranked among companies with meaningful PS Ratio only.
BIO' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.63 Max: 4.35
Current: 4.23
0.87
4.35
Price-to-Free-Cash-Flow 82.93
BIO's Price-to-Free-Cash-Flow is ranked lower than
99% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. BIO: 82.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.64  Med: 25.63 Max: 517.52
Current: 82.93
9.64
517.52
Price-to-Operating-Cash-Flow 44.44
BIO's Price-to-Operating-Cash-Flow is ranked lower than
93% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. BIO: 44.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.5  Med: 13.34 Max: 78.07
Current: 44.44
7.5
78.07
EV-to-EBIT 6.96
BIO's EV-to-EBIT is ranked lower than
91% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. BIO: 6.96 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.4  Med: 14.5 Max: 179.9
Current: 6.96
6.4
179.9
EV-to-EBITDA 6.24
BIO's EV-to-EBITDA is ranked lower than
77% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. BIO: 6.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 9.7 Max: 39.4
Current: 6.24
5.7
39.4
EV-to-Revenue 3.97
BIO's EV-to-Revenue is ranked higher than
56% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. BIO: 3.97 )
Ranked among companies with meaningful EV-to-Revenue only.
BIO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 1.6 Max: 4.1
Current: 3.97
1
4.1
Shiller PE Ratio 42.97
BIO's Shiller PE Ratio is ranked lower than
59% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. BIO: 42.97 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.63  Med: 28.72 Max: 60.82
Current: 42.97
19.63
60.82
Current Ratio 4.50
BIO's Current Ratio is ranked higher than
67% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. BIO: 4.50 )
Ranked among companies with meaningful Current Ratio only.
BIO' s Current Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.67 Max: 4.52
Current: 4.5
1.49
4.52
Quick Ratio 3.17
BIO's Quick Ratio is ranked higher than
60% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BIO: 3.17 )
Ranked among companies with meaningful Quick Ratio only.
BIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.72 Max: 3.45
Current: 3.17
0.82
3.45
Days Inventory 210.25
BIO's Days Inventory is ranked lower than
90% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. BIO: 210.25 )
Ranked among companies with meaningful Days Inventory only.
BIO' s Days Inventory Range Over the Past 10 Years
Min: 158.55  Med: 179.11 Max: 210.25
Current: 210.25
158.55
210.25
Days Sales Outstanding 64.61
BIO's Days Sales Outstanding is ranked lower than
63% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. BIO: 64.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.37  Med: 70.54 Max: 78.54
Current: 64.61
63.37
78.54
Days Payable 92.31
BIO's Days Payable is ranked lower than
99.99% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. BIO: 92.31 )
Ranked among companies with meaningful Days Payable only.
BIO' s Days Payable Range Over the Past 10 Years
Min: 43.27  Med: 52.24 Max: 92.31
Current: 92.31
43.27
92.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
BIO's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. BIO: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: -1 Max: -0.2
Current: -0.8
-1.3
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 38.67
BIO's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. BIO: 38.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.86  Med: 7.17 Max: 95.94
Current: 38.67
2.86
95.94
Price-to-Tangible-Book 2.38
BIO's Price-to-Tangible-Book is ranked higher than
71% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. BIO: 2.38 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.73  Med: 2.52 Max: 6.43
Current: 2.38
0.73
6.43
Price-to-Intrinsic-Value-Projected-FCF 2.14
BIO's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
53% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BIO: 2.14 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.45 Max: 20.39
Current: 2.14
0.78
20.39
Price-to-Median-PS-Value 2.58
BIO's Price-to-Median-PS-Value is ranked lower than
88% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. BIO: 2.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.73 Max: 2.67
Current: 2.58
0.14
2.67
Price-to-Peter-Lynch-Fair-Value 1.60
BIO's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. BIO: 1.60 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.53 Max: 46.3
Current: 1.6
0.49
46.3
Price-to-Graham-Number 0.99
BIO's Price-to-Graham-Number is ranked higher than
55% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. BIO: 0.99 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.67  Med: 1.48 Max: 8.75
Current: 0.99
0.67
8.75
Earnings Yield (Greenblatt) % 14.37
BIO's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. BIO: 14.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 6.9 Max: 15.6
Current: 14.37
0.6
15.6
Forward Rate of Return (Yacktman) % 6.64
BIO's Forward Rate of Return (Yacktman) % is ranked lower than
96% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. BIO: 6.64 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -12.6  Med: 8.6 Max: 21.9
Current: 6.64
-12.6
21.9

More Statistics

Revenue (TTM) (Mil) $2,282.87
EPS (TTM) $ 34.13
Beta1.05
Volatility33.56%
52-Week Range $208.95 - 345.15
Shares Outstanding (Mil)29.84

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 2,291 2,370 2,474
EBIT (Mil $)
EBITDA (Mil $) 368 420 471
EPS ($) 6.04 7.46 8.91
EPS without NRI ($) 6.04 7.46 8.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}